Department of Biology, Fort Lewis College, 1000 Rim Drive, Durango, CO 81301, USA.
Bioorg Med Chem Lett. 2013 Jan 15;23(2):562-4. doi: 10.1016/j.bmcl.2012.11.017. Epub 2012 Nov 16.
The first report of the antiviral activity of (+)-sattabacin against varicella-zoster virus (VZV) is described. Our results show that (+)-sattabacin potently inhibits the growth of VZV at concentrations in the range of other drugs commonly prescribed for VZV infection. Experiments detailing the synthesis of (+)-sattabacin, quantification of cytotoxicity and gene expression data in human fibroblast cells are also presented. Gene expression data was obtained through microarray analysis from human fibroblast cells exposed to sattabacin in order to identify a possible mechanism by which (+)-sattabacin inhibits VZV replication.
首次报道了 (+)-sattabacin 对水痘带状疱疹病毒 (VZV) 的抗病毒活性。我们的结果表明，(+)-sattabacin 能够在与其他常用于治疗 VZV 感染的药物相当的浓度范围内强力抑制 VZV 的生长。本文还详细介绍了 (+)-sattabacin 的合成、人成纤维细胞细胞的细胞毒性定量和基因表达数据。通过对暴露于 sattabacin 的人成纤维细胞进行微阵列分析获得了基因表达数据，以确定 (+)-sattabacin 抑制 VZV 复制的可能机制。
